Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21872357 | 0.81 | SLC6A3 (0.47) | SLC6A3KDM4EALDH1A1HSD17B10KLK7 | |
| SCHEMBL13982744 | 0.81 | SLC6A3 (1.00) | SLC6A3 | |
| SCHEMBL11267858 | 0.78 | SLC6A3 (0.71) | SLC6A3 | |
| SCHEMBL16012005 | 0.78 | SLC6A3 (0.60) | SLC6A3SMN1; SMN2 | |
| SCHEMBL9126255 | 0.77 | L3MBTL1 (0.72) | KDM4EALDH1A1HSD17B10TSHRSMN1; SMN2 | |
| SCHEMBL2577670 | 0.77 | SLC6A3 (0.65) | SLC6A3ALDH1A1TSHR | |
| SCHEMBL12837404 | 0.77 | HSD17B10 (0.59) | KDM4EALDH1A1HSD17B10TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2577794 | 0.76 | SLC6A3 (0.62) | SLC6A3ALDH1A1TSHR | |
| SCHEMBL16011914 | 0.76 | SLC6A3 (0.67) | SLC6A3 | |
| SCHEMBL1121660 | 0.74 | SLC6A3 (0.66) | SLC6A3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113038942-A | Composition for treating fibrotic diseases containing benzhydrylthioacetamide (Benzhydryl ttoacetamide) compound as active ingredient | 细胞离子生物医学株式会社 | 2021-06-25 | — | — | CN | claimed |
| US-9259412-B2 | Composition of the treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or derivatives thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-02-16 | — | — | US | disclosed |
| US-9259412-B2 | Composition of the treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or derivatives thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-02-16 | — | — | US | disclosed |
| US-20140296333-A1 | COMPOSITION OF THE TREATMENT OF VASCULAR DISEASES OR KCa3.1 CHANNEL-MEDIATED DISEASES COMPRISING MODAFINIL OR DERIVATIVES THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296333-A1 | COMPOSITION OF THE TREATMENT OF VASCULAR DISEASES OR KCa3.1 CHANNEL-MEDIATED DISEASES COMPRISING MODAFINIL OR DERIVATIVES THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296333-A1 | COMPOSITION OF THE TREATMENT OF VASCULAR DISEASES OR KCa3.1 CHANNEL-MEDIATED DISEASES COMPRISING MODAFINIL OR DERIVATIVES THEREOF | KCNN3, KCNA3, KCNK3 | SLC6A3 243/4885KDM4E 1340/4885ALDH1A1 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.